The arylsulfanylpyrazolone and aryloxanylpyrazolone scaffolds previously were reported to inhibit Cu/Zn superoxide dismutase 1 dependent protein aggregation and to extend survival in the ALS mouse model. However, further evaluation of these compounds indicated weak pharmacokinetic properties and a relatively low maximum tolerated dose. On the basis of an ADME analysis, a new series of compounds, the arylazanylpyrazolones, has been synthesized, and structure−activity relationships were determined. The SAR results showed that the pyrazolone ring is critical to cellular protection. The NMR, IR, and computational analyses suggest that phenol-type tautomers of the pyrazolone ring are the active pharmacophore with the arylazanylpyrazolone analogues. A comparison of experimental and calculated IR spectra is shown to be a valuable method to identify the predominant tautomer.
■ INTRODUCTION
Amyotrophic lateral sclerosis (ALS), a rapidly fatal neurodegenerative disease, is characterized by progressive loss of upper and/or lower neurons in the motor cortex, brainstem, and ventral spinal cord. 1 Although the incidence and prevalence of the disease are relatively low compared with other neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, it has the most rapid progression to death, in most cases within 3−5 years after diagnosis. 2 Moreover, an observed increased prevalence, 3 higher risk for military personnel, 4 and high cost for care in the late stages of ALS 5 result in extreme economic and emotional burdens to the patients and their families, nearly one-third of whom reside in the United States. 6 The sole FDA-approved drug riluzole, a presumptive antiglutamatergic agent, extends survival by only 2−3 months. 7 Although the mechanistic basis of ALS and the cause of motor neuron death remain controversial, a cohort of susceptibility genes producing ALS have been identified from familial ALS patients, 8 such as fused in sarcoma, senataxin, TAR DNA binding protein (TDP-43), and UBQLN2. The discovery of the toxicity of mutant Cu/Zn superoxide dismutase 1 (SOD1) provides the first insight into potential causes for ALS 9 and contributes the most to our understanding of ALS pathology, which includes calcium mediated excitotoxicity, oxidative stress, mitochondrial dysfunction, and aberrant RNA processing. 10 Recent observations that mutant SOD1-expressing astrocytes are toxic to motor neurons in both familial and sporadic ALS, 11, 12 together with the fact that SOD1 mediated protein misfolding and aggregation have proven to be associated with ALS pathogenesis, 13 suggest a possible therapeutic treatment involving protection against mutant SOD1-induced cytotoxicity. We therefore developed an assay using PC12 cells expressing G93A SOD1 14 and carried out a high-throughput screen to identify compounds that protected these cells from protein aggregation and toxicity. 15 One of the hit scaffolds was the arylsulfanylpyrazolones (ASPs), which exhibited good in vitro potency but was rapidly metabolized. 16 The metabolic hot spot was identified as the sulfur atom, which was readily oxidized. Conversion to the corresponding ether led to much more stable compounds, and one analogue extended the life of G93A ALS mice by 13.3% at 20 mg/kg. 17 A SAR study characterized the important parts of this class of compounds. 18 In a search of more potent and metabolically stable compounds, which also would allow diverse substitutions to carry out target identification studies, we synthesized the corresponding arylazanylpyrazolones (AAPs). These compounds are the focus of this paper ( Figure 1 ).
■ RESULTS AND DISCUSSION
Chemistry. Two synthetic strategies were utilized to synthesize β-ketoesters, the critical intermediate for the construction of the pyrazolone ring. As shown in Scheme 1, the upper route started from the reaction of alkylanilines or sulfonylamides with ethyl bromoalkanoate. The ester intermediates reacted with the enolate of ethyl acetate, providing the anilino substituted β-ketoesters in moderate to high yields. The lower single-step route was carried out using an optimized methodology 19 based on the reaction of the aniline with ethyl 4-chloroacetoacetate, resulting in a series of anilino substituted β-ketoester intermediates with varied R and R′ substituents. All of the β-ketoester intermediates were transformed to pyrazolones in high yields with hydrazine.
An alternative synthetic route (Scheme 2) was designed for bulky R groups such as tert-butyl, phenyl, and benzyl, which gave low yields of anilino esters in the reaction above. By employment of ethyl diazoacetate, an NH insertion occurred to achieve the anilino esters in good yields, 20 which were used to generate the β-ketoester intermediates by attack of the enolate of ethyl acetate.
The N 1 -methylpyrazolone analogue (30) was easily obtained by replacing hydrazine with methylhydrazine in the heterocycle formation (Scheme 3). The N 1 -methylpyrazolones can be further modified to dimethyl-and trimethyl-substituted pyrazolone analogues (32−34). Although it has been reported that the condensation between methylhydrazine and a β-ketoester produces a mixture of N 1 -alkyl and N 2 -alkyl isomers, 21 no N 1 -alkyl product was observed with our substrate. With the help of a method developed by Janin and co-workers, 22 our attempts to synthesize the N 2 -alkyl product (31) were successful, as shown in Scheme 3. The β-ketoester intermediate was initially converted to N 1 -2-hydroxylethyl-N 2 -tosylpyrazolone derivative 35 in an 85% yield, which was then treated with sodium hydride to give key intermediate 36 containing a 2,3-dihydropyrazolo [3,2-b] oxazole ring. Alkylation with MeOTf and dihydrooxazole ring-opening with sodium iodide followed by elimination of hydrogen iodide led to N 1 -vinyl-N 2 -methylpyrazolone 37 in a 55% yield. Acid hydrolysis gave the desired N 1 -methylpyrazolone analogue (31) . In Vitro Activity of Secondary and Tertiary AAPs. Compound 1 has an oral bioavailability of 27%, PK half-life of 3.6 h, and maximum tolerated dose of 75 mg/kg, which meet the standard minimal criteria for preclinical advancement. 23 However, some pharmacokinetic properties of 1 need improvement. For example, as indicated by the oral bioavailability, 17 the AUC/dose of 1 showed a distinct difference between iv (184 (ng·h/mL)/dose) and po (50 (ng·h/mL)/dose) administration. Given good aqueous solubility and cell permeability, one of the most likely causes for the difference between these two routes of administration is the first-pass clearance from hepatic and gut metabolism. 24 To increase metabolic stability and further diversify the structure, the ether oxygen was replaced by the isosteric amine functional group.
Two possible amines, secondary and tertiary AAP analogues, were initially screened in the protection assay ( Figure 2 ) and for in vitro microsomal stability (Table 1) and Caco-2 permeability ( Table 2) . Introduction of the nitrogen led to a potency decrease in the cell-based protection assay; however, the tertiary arylazanyl analogue had a slightly better activity over the secondary arylazanyl analogue. The solubilities of 2 and 3 were good in aqueous media (≥150 μM), and no precipitation occurred at the highest concentration. The in vitro plasma half-life for both compounds was >60 min. Tertiary amine 3 exhibited a remarkable stability enhancement in human liver microsomes compared with the moderate half-lives and clearance rates of the ether and secondary amine analogues. Whereas 1 had excellent permeability and low efflux potential toward Caco-2, neither 2 nor 3 exhibited satisfactory Caco-2 permeability and both had high efflux potential, although 3 was superior to 2.
These preliminary results suggest that the AAPs may not be an improvement over the aryloxanylpyrazolone series, but the tertiary amine analogue (3) showed improved human microsome stability, so a library of tertiary amine analogues was synthesized.
SAR of AAP Analogues. Compound activity was determined using the previously described cytotoxicity protection assay (Table 1 , Supporting Information). 15 The variability of the EC 50 values is about a factor of 2. As shown in Figure 1 , the tertiary amine AAP scaffold contains four substructural moieties: aromatic ring, N-substituent, linker, and the pyrazolone. Structural modifications were conducted on each moiety. A variety of substituents in the aryl moiety was investigated using our previous synthetic method for amination of anilines and γ-halogen-β-ketoesters ( Figure 3 ). In general, the potencies of these AAPs were slightly poorer than those of the ether counterparts (1 vs 3 25 ). Our previous reports on arylsulfanyl- 16 and aryloxanylpyrazolones 17 (AXP) showed that the 3,5-dichloro substitution pattern in the aromatic ring gave greater potency over the other substitution patterns (about 5-to 10-fold enhancement). Here, neither the electronic properties (compounds 4−6) nor the positions of substitution (compounds 9−11) in the aromatic ring exhibited a large activity change, but the size of the substituents affected the activity in the following order: F < CN < OMe < Cl ∼ Br < diCl ∼ naphthalene. 2,4-Dichloro-and α-naphthyl substitutions in the aromatic ring moiety were the most effective. With the aromatic ring substituents, linker, and pyrazolone held constant, a series of N-substituted AAPs was synthesized ( Figure 4 ; these compounds were being synthesized prior to the measurements in Figure 3 , so 3,5-dichloro was selected for aryl substitution). Although the range of potency changed by less than 4-fold, the ethyl analogue was the most potent and the potency decreased with an increase of the size of substituents in the following order: Et > c-Pr > i-Pr ∼ Bn > propargyl > t-Bu ∼ Ph; however, the smaller methyl analogue was comparable in potency to the cyclopropyl analogue. The propargyl analogue will be beneficial to our ongoing target identification studies, providing a terminal triple bond for reporter group attachment via click chemistry. 26 An investigation of the linker between the aryl moiety and the pyrazolone also was carried out to determine the influence of length and shape. As shown in Figure 5 , one carbon is the optimal length between the nitrogen and the pyrazolone moiety; longer linkers reduce the activity.
One useful modification to enhance the pharmacokinetic properties is a ring−chain transformation. 27 Four ring linkers were introduced to the AAP scaffold (25−28) . The connection between the aryl group and the N-substituent (25 and 26) favored 26. The linker between the N-substituent and the pyrazolone ring (27 and 28) has a preference for that described by 28. The latter two compounds reveal that substitution at the 5-position of the pyrazolone does not affect potency.
Selected compounds were tested with cortical neurons, which is critical prior to the expensive and time-consuming ALS mouse model studies. 28 Although long linker compound 24 and cyclic linker compound 27 are active in the PC12 assay, they are not active with cortical neurons. Compound 3 gave better results than the ether counterpart (1), recovering 100% neuronal activity at 10 μM (Supporting Information).
Pharmacophoric Nature of the Pyrazolone Ring. According to our previous studies, the pyrazolone ring is the key functional group for activity in all of the AXP scaffolds. The compounds without a pyrazolone or with N,N′-dimethyl substituted pyrazolone in the aryloxanyl series had no activity. 17 Given that there are three potential H-bonding donors/ acceptors in the pyrazolone ring, a determination of their pharmacophoric nature is important. In our recent paper, 18 a putative explanation for the pyrazolone activity was the availability of the N 2 -hydrogen (3a-type, Figure 7 ) for hydrogen bonding. To determine if the same moiety was essential for the AAP class of compounds, single N 2 -nitrogen substituted pyrazolone analogue 31 and other substituted pyrazolone analogues were synthesized (Scheme 3). As shown in Figure 6 , 29 and 30 were comparable in activity to parent compound 3, while compounds 31−34, all of which do not have a N 2 -H, were devoid of activity, demonstrating the significance of the N 2 -H for activity in this series as well. Several spectrometric analyses were carried out to determine if the pyrazolone structure shown in Figure 7 is the most prevalent. Because of a rapid equilibrium among the pyrazolone tautomers, the 13 C NMR spectrum of 3 gave a carbon signal with obscure bumps in the region of the pyrazolone and methylene group. However, clear 13 C NMR spectra of those carbons in 30 and 31 suggested a predominant tautomer. HSQC, HMBC, and NOE spectra of 30 and 31 were then collected. The HSQC spectrum permitted the assignment of all of the protons with their bonding carbons. Analysis of the HMBC spectrum enabled the connectivity of the phenyl, the linker, and the pyrazolone moieties. The cross peaks between the phenol hydrogen and the 4-hydrogen of the pyrazolone in the NOE spectrum determined the spatial approach of these two neighboring hydrogens, which supported the predominant tautomer in 30 and 31 as the phenol form (30b and 31b, Figure 7 ).
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In an attempt to rationalize these observations, comprehensive theoretical calculations were performed on the four possible tautomers of 3 using density-functional theory (DFT); the predicted energy order was 3d < 3b < 3c < 3a in the gas phase ( Table 3 ). The largest energy difference among all of the forms is 22.6 kJ/mol, which is an insufficient energy barrier to detect a preferred tautomeric form. Since the tautomerization of pyrazolone was first discovered by Knorr in 1895, 29 several reported calculations have predicted a similar prediction for the stability of the pyrazolone tautomers, 30 and calculations of similar structures predicted that the phenol forms are favored for 1-or 2-substituted pyrazolones in aprotic solvents, 20 ,31 as we observed. To further characterize the predominant tautomeric form of the pyrazolone heterocycles in 30 and 31, we performed quantum chemical calculations ( Figure 8 ). The predominant conformation can be identified by comparing the experimental IR spectra with the predicted IR spectra of the different tautomers. All of the predicted spectra of keto tautomers have a similar high frequency at ∼1730 cm −1 , while the spectra of phenol-type tautomers have no absorption band in the same region. Hence, the frequency at ∼1730 cm −1 , the stretching vibration of the CO bond, is an important band to differentiate these two tautomers. The experimental IR spectra do not contain a band at 1730 cm
. Furthermore, the most highly predictive bands for phenol forms are in good agreement with the experimental data. All of these results indicate that phenol forms of 30 and 31 are the more stable tautomers. Similar NOE and IR spectral observations for ether analogue 38 32 suggest that the active pyrazolone tautomer in the AOP series also is the phenol form (see Supporting Information and Figure 8C ).
On the basis of the above results, we conclude that the pyrazolone phenol-type tautomer is predominant in solution and in solid phase, but given that the target(s) is unknown, we cannot conclude definitively whether this tautomer is the pharmacophoric core responsible for the activity of all AAP and AOP analogues. If that tautomer is the active tautomer, then biological activity requires the following two criteria: (1) N 2 has unsubstituted sp 2 hybridization rather than sp 3 hybridization; (2) there is a phenol hydrogen, presumably as a H-bonding donor. The loss of activity by di-and trimethyl substituted derivatives also supports the hypothesis that both criteria must be met for activity.
■ CONCLUSION
Aryloxanyl analogues were previously identified as potential drug candidates exhibiting good potency, ADME properties, and equivalent or slightly better results with the ALS mouse model as did the FDA-approved drug riluzole. However, because of its structural limitations, the aryloxanyl analogues may not be suitable as a chemical probe for a biological target study and need further optimization to improve in vivo activity.
The AAP analogues showed superior properties relative to the corresponding ether derivative in potential structural diversity and in preliminary metabolic studies. Conclusions from the SAR study are as follows: (1) the size of the aryl moiety, rather than the electronic properties, is important for good potency; (2) potency decreases when the size of the Nsubstituents increase; as a potential chemical reporter, the alkynyl group is well tolerated; (3) one carbon is the optimum length for the linker; the linker can be linear or cyclic; (4) the pyrazolone moiety is the only critical pharmacophore of this structure for activity, which prefers the phenol-type tautomer in solution and solid phase, although it is not known if it binds to any targets in that form; (5) a comparison of the predicted and experimental IR spectra is useful to identify the predominant tautomer of a heterocyclic system. These results support further development of AAP analogues as a reagent for target identification and as a novel drug candidate for the treatment of ALS.
■ EXPERIMENTAL SECTION
General Experimental Methods. All reactions were carried out with magnetic stirring and were monitored by thin-layer chromatography on precoated silica gel 60 F254 plates. Column chromatography was performed with silica gel 60 (230−400 mesh). Proton and carbon NMR spectra were recorded in deuterated solvents on a Bruker Ag500 (500 MHz) spectrometer. The chemical shifts were reported in δ (ppm) ( 1 H NMR: CDCl 3 , δ 7.26 ppm; DMSO-d 6 , δ 2.50 ppm. 13 C NMR: δ 77.23 ppm; DMSO-d 6 , δ 39.52 ppm). The following abbreviations were used to define the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet. Electrospray mass spectra were obtained using an Agilent 1100 MSD instrument with methanol as the solvent in the positive ion mode. IR was recorded on a Bruker TENSOR FT-IR spectrometer. Elemental microanalysis was performed by Atlantic Microlab Inc. (Norcross, GA). The C, H, and N analyses were performed by combustion using automatic analyzers, and all of the compounds analyzed showed >95% purity. All reagents purchased from Aldrich, Alfa Aesar, and TCI were used without further purification unless stated otherwise.
General Procedure A for Nucleophilic Amination of Anilines and Bromoacetates. To a solution of K 2 CO 3 (200 mol %) and the aniline (1.0 equiv) in DMF (2 mL/mmol) was added ethyl bromoacetate (150 mol %). The reaction mixture was stirred at room temperature or 80°C for 16 h. The reaction solution was diluted with ethyl acetate, washed twice with water to remove the reaction solvent, and washed with brine. The collected organic layers were combined, dried over Na 2 SO 4 , filtered, and concentrated. The crude product was purified on a silica gel column, eluting with a mixture of ethyl acetate and hexane (5−20% ethyl acetate) to afford the product as a colorless to pale yellow oil in a yield of 30−80%.
General Procedure B for Carbene Insertion of Anilines. To a solution of the aniline (1.0 equiv) and Rh 2 (OAc) 4 (2 mol %) in anhydrous dichloromethane (1 mL/mmol) was added ethyl diazoacetate dropwise. Caution: Much N 2 is released! The reaction mixture was stirred at room temperature for 1 h. After evaporation of the volatiles, the reaction residue was purified on a silica gel column, eluting with a mixture of ethyl acetate and hexane (5−20% ethyl acetate) to afford the product as a colorless to pale yellow oil in a yield of 50−95%.
General Procedure C for the Synthesis of β-Ketoesters from Aminoacetates. Ethyl acetate (110 mol %) was added to a THF (5 mL/mmol) solution of LiHMDS (1 N in THF, 120 mol %) at −78°C and stirred for 60 min. A THF (1 mL/mmol) solution of β-aminoacetate (1.0 equiv) was added dropwise to the reaction mixture at −78°C. After the resulting solution was stirred at −78°C for another 2 h, the reaction mixture was quenched with saturated NH 4 Cl. The aqueous layer was extracted with ethyl acetate and washed twice with water and brine. The collected organic layers were combined, dried over Na 2 SO 4 , filtered, and concentrated. The crude product was purified on a silica gel column, eluting with a mixture of ethyl acetate and hexane (10−30% ethyl acetate) to afford the product as a colorless to pale yellow oil in a yield of 40−80%.
General Procedure D for Direct Amination of γ-Halo-β-ketoesters with Anilines. To a solution of NaHCO 3 (200 mol %), NaI (200 mol %), and the aniline (1 equiv) in acetonitrile (1 mL/mol) was added ethyl α-chloracetoacetate (200 mol %). The resulting reaction mixture was stirred at room temperature or at 80°C for 1−16 h. After the mixture was cooled to room temperature, saturated Na 2 S 2 O 3 solution (1 mL/mol) was added. The resulting solution was extracted with ethyl acetate, and the organic layer was collected, which was then washed with water and brine. The collected organic layers were combined, dried over Na 2 SO 4 , filtered, and concentrated. The residue was subjected to column chromatography, eluting with a mixture of hexane and ethyl acetate (10−30% ethyl acetate) to afford the product as a pale yellow oil in a yield specified in the our published method of amination. 19 General Procedure E for the Synthesis of Pyrazolones from β-Ketoesters. To a solution of β-ketoesters (1 equiv) in EtOH (5 mL/mmol) was added anhydrous hydrazine (200 mol %). The resulting solution was stirred at room temperature overnight. After evaporation of the volatiles, the reaction residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (2−10% MeOH) to afford the product as a colorless to pale pink solid. The solid was then recrystallized in dichloromethane/hexane to give the pure product as a white solid in a yield of 60−75%. O, 4 mL) and AcOH (4 mL). After the resulting suspension was stirred at 100°C for 2 h, the reaction mixture was partitioned between 1 N HCl (10 mL) and ethyl acetate (30 mL × 2). The collected organic layers were combined, dried over Na 2 SO 4 , filtered, and concentrated. The residue was subjected to column chromatography, eluting with a mixture of MeOH and dichloromethane (5% MeOH) to afford 2 (142 mg, 55% yield) as a white solid. 1 11 (s, 1H), 4.17 (s, 2H), 1.12 (m, 9H) . 13 C 5-((Cyclopropyl(3,5-dichlorophenyl)amino)methyl)-1H-pyrazol-3(2H)-one (19) . The title compound was prepared according to general procedures B, C, and E. (36) . To a solution of ethyl 4-((3,5-dichlorophenyl)(methyl)amino)-3-oxobutanoate (304 mg, 1.0 mmol) in EtOH (5 mL) was added 2-hydroxyethylhydrazine (85 uL, 1.1 mmol), and the mixture was stirred for 3 h. After evaporation of the volatiles, the residues were dissolved with dry acetonitrile (10 mL) and triethylamine (156 uL, 1.1 mmol) followed by the addition of tosyl chloride (190 mg, 1.0 mmol). The solution was stirred for 20 min, diluted in ethyl acetate (20 mL), washed with water (10 mL), dried over Na 2 SO 4 , and concentrated. The residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (2% MeOH) to afford the product as a pale yellow liquid 35 (400 mg, 85%).
Under an inert atmosphere, 35 was dissolved in anhydride acetonitrile (8.5 mL) followed by the addition of sodium hydride (40 mg, 1.0 mmol). The mixture was stirred overnight at room temperature and evaporated to give the residue, which was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (1% MeOH) to afford the product as a pale yellow solid 36 (200 mg, 79%). 5-(((3,5-Dichlorophenyl)(methyl)amino)methyl)-1-methyl-2-vinyl-1H-pyrazol-3(2H)-one (37) . To a solution of compound 36 (200 mg, 0.67 mmol) in anhydrous acetonitrile (6 mL) was added methyl trifluoromethanesulfonate (85 μL, 0.75 mmol), and the solution was stirred for 2 h before the addition of sodium iodide (195 mg, 1.3 mmol) and TsOH (127 mg, 0.67 mmol). After conversion to the iodinated intermediate by overnight stirring, KO-tBu (188 mg, 1.7 mmol) was added to the mixture, which was further stirred for 1 h. After evaporation of the volatiles, the residue was purified on a silica gel column, eluting with a mixture of MeOH and dichloromethane (4% MeOH) to afford the product as a yellow liquid (115 mg, 55%). 1 Mutant SOD1-Induced Cytotoxicity Protection Assay. Viability and EC 50 values were determined for 1a, 1b, 2a, and 2b according to the previously reported assay procedure.
15 PC12 cells were seeded at 15 000 cells/well in 96-well plates and incubated 24 h prior to compound addition. Compounds were assayed in 12-point dose−response experiments to determine potency and efficacy. The highest compound concentration tested was 32 μM, which was decreased by one-half with each subsequent dose. After a 24 h incubation with the compounds, MG132 was added at a final concentration of 100 nM. MG132 is a well-characterized proteasome inhibitor, which would be expected to enhance the appearance of protein aggregation by blocking the proteosomal clearance of aggregated proteins. Cell viability was measured 48 h later using the fluorescent viability probe Calcein-AM (Molecular Probes). Briefly, cells were washed twice with PBS. Calcein-AM was added at a final concentration of 1 μM for 20 min at room temperature, and fluorescence intensity was read in a POLARstar fluorescence plate reader (BMG). Fluorescence data were coupled with compound structural data, then stored and analyzed using the CambridgeSoft Chemoffice Enterprise Ultra software package.
In Vitro ADME Assays. In vitro microsomal stability, aqueous solubility, and Caco-2 permeability were determined for 1b and 2b at Apredica Inc. (Watertown, MA).
Computational Methods. Possible initial tautomer structures were constructed with molecular modeling software Sybyl-X 1.2 (Tripos International, St. Louis, MO). After primary optimization by use of MM2 molecular mechanical module encoded in the program CS Chem3D, these two structures were subjected to full optimization within the density-functional theory (DFT). The Lee−Yang−Parr correlation functional approximation (B3LYP) method was used in a 6-31+G(d,p) basis set. 35, 36 On the basis of the optimized geometries, energy or frequency calculations were carried out at the same levels of B3LYP to verify the reasonability of the optimized structures. A frequency scaling factor of 0.964 was used in the comparison of the calculated results with the experimental spectra. 37 All of the Quantum Chemical calculations were carried out with the Gamess (2012R1) program. 
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